Quoi de neuf en oncodermatologie ?
暂无分享,去创建一个
[1] A. Hauschild,et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.
[2] V. Sondak,et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial , 2022, The Lancet.
[3] Lin F. Yang,et al. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet.
[4] P. Ascierto,et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. , 2022, The Lancet. Oncology.
[5] P. Hwu,et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. , 2022, The Lancet. Oncology.
[6] D. Schadendorf,et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] V. Gebski,et al. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study. , 2022, The Lancet. Oncology.
[8] C. Lebbé,et al. Managing immune checkpoint inhibition in transplant recipients. , 2022, The Lancet. Oncology.
[9] M. Bagot,et al. Large‐cell transformation is an independent poor prognostic factor in Sézary syndrome: analysis of 117 cases , 2022, The British journal of dermatology.
[10] A. Lallas,et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. , 2022, European journal of cancer.
[11] J. Utikal,et al. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Palefsky,et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. , 2022, The New England journal of medicine.
[13] C. Huh,et al. Real-time, In Vivo Skin Cancer Triage by Laser-Induced Plasma Spectroscopy Combined with Deep Learning-based Diagnostic Algorithm. , 2022, Journal of the American Academy of Dermatology.
[14] K. Shannon,et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial , 2022, Nature Medicine.
[15] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. , 2022, European journal of cancer.
[16] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.
[17] C. Lebbé,et al. IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. , 2022, Cancer cell.
[18] Nathan E. Reticker-Flynn,et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis , 2022, Cell.
[19] D. Schadendorf,et al. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. , 2022, The New England journal of medicine.
[20] M. Khodadoust,et al. Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma. , 2022, Blood.
[21] S. Ai,et al. Preoperative 3D Reconstruction Model in Slow Mohs Surgery for Dermatofibrosarcoma Protuberans , 2022, Computational intelligence and neuroscience.
[22] A. Marghoob,et al. Melanoma with peripheral globules: clinical and dermoscopic features. , 2022, Journal of the American Academy of Dermatology.
[23] C. Schauer,et al. Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial , 2022, The Lancet.
[24] D. Boll,et al. The Paget Trial: Topical 5% imiquimod cream for non-invasive vulvar Paget disease. , 2022, American journal of obstetrics and gynecology.
[25] D. Schadendorf,et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial , 2022, The Lancet.
[26] F. Bray,et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. , 2022, JAMA dermatology.
[27] O. Merimsky,et al. Phase 2 single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi Sarcoma (cKS). , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] A. Dupuy,et al. The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy. , 2022, Journal of the National Cancer Institute.
[29] G. Carcelain,et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. , 2022, The Lancet. Oncology.
[30] T. Spector,et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma , 2022, Nature Medicine.
[31] D. Schadendorf,et al. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , 2022, European journal of cancer.
[32] R. Clark,et al. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas , 2022, Blood advances.
[33] E. Sattler,et al. Line-Field Confocal Optical Coherence Tomography: A New Tool for the Differentiation between Nevi and Melanomas? , 2022, Cancers.
[34] Li Zhou,et al. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy , 2022, Melanoma research.
[35] M. Weichenthal,et al. Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] K. Shannon,et al. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. , 2022, JAMA surgery.
[37] D. Hartmann,et al. Line-Field Confocal Optical Coherence Tomography Increases the Diagnostic Accuracy and Confidence for Basal Cell Carcinoma in Equivocal Lesions: A Prospective Study , 2022, Cancers.
[38] M. Marchetti,et al. Skin Cancer: Primary, Secondary, and Tertiary Prevention. Part I. , 2022, Journal of the American Academy of Dermatology.
[39] M. Bagot,et al. Involvement of the CD39/CD73/adenosine pathway on T cell proliferation and NK cell-mediated ADCC in Sézary syndrome. , 2022, Blood.
[40] V. Mailänder,et al. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma , 2022, Cells.
[41] L. Biard,et al. Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome * , 2022, The British journal of dermatology.
[42] J. Malvehy,et al. Non-invasive scoring of cellular atypia in keratinocyte cancers in 3D LC-OCT images using Deep Learning , 2022 .
[43] R. Scolyer,et al. Dermoscopic features and screening strategies for the detection of small‐diameter melanomas , 2022, Clinical and experimental dermatology.
[44] D. Schadendorf,et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. , 2022, The New England journal of medicine.
[45] U. Wehkamp,et al. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop * , 2022, The British journal of dermatology.
[46] J. Utikal,et al. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.
[47] P. de la Grange,et al. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing and disease control in mogamulizumab-treated CTCL patients. , 2021, Blood.
[48] J. Pearson,et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. , 2021, Cancer cell.
[49] D. Schadendorf,et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Marisa C. Jenkins,et al. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. , 2021, JAMA dermatology.
[51] L. Schwartz,et al. Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. , 2021, Blood.
[52] S. Pileri,et al. Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma , 2021, Cancer.
[53] I. Johansson,et al. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[54] A. Lallas,et al. Dermoscopy of nodular/plaque-type primary cutaneous T- and B-cell lymphomas: a retrospective comparative study with pseudolymphomas and tumoral/inflammatory mimickers by the International Dermoscopy Society. , 2021, Journal of the American Academy of Dermatology.
[55] M. Millward,et al. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression , 2021, British Journal of Cancer.
[56] M. Pindo,et al. Early melanoma invasivity correlates with gut fungal and bacterial profiles , 2021, The British journal of dermatology.
[57] Jason M. Johnson,et al. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2021, Clinical Cancer Research.
[58] B. Dréno,et al. Change in lentigo maligna score assessed by in vivo reflectance confocal microscopy after one month of imiquimod treatment for lentigo maligna management. , 2021, Journal of the American Academy of Dermatology.
[59] A. Lallas,et al. Dermoscopy of early melanomas: variation according to the anatomic site , 2021, Archives of Dermatological Research.